News
Novo Nordisk’s Wegovy, the blockbuster weight loss drug, debuts in India: How much will it cost, who needs it, key benefits
Danish pharma giant Novo Nordisk on Tuesday launched its blockbuster weight loss drug Wegovy as a once-a-week injection in India. This adds to the option of weight loss drugs with Eli Lilly’s injectable Mounjaro now also available in the country.
Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over ...
In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...
Novo Nordisk A/S is hunting for more early-stage deals to pad its pipeline of next-generation obesity drugs, as the drugmaker ...
Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...
Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...
Results for weight-loss drug targeting amylin find similar efficacy across different doses and high rates of side effects, ...
The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...
Novo Nordisk shares have come under pressure amid weight-loss drug competition, while UK health officials have launched a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback